PRESS RELEASES

10-2018
Biopharmaceutical company Aegerion joins AELMHU

"The biopharmaceutical company Aegerion has joined the Spanish Association of Orphan and Ultra-rare Medicines Laboratories (AELMHU), the organisation that brings together leading pharmaceutical and biotechnology companies committed to investing in the development of new therapies capable of improving the situation of patients suffering from rare and ultra-rare diseases.

Acquired by Novelion Therapeutics in November 2016, Aegerion is a biopharmaceutical company dedicated to developing innovative therapies to improve the lives of people living with rare metabolic diseases with limited therapeutic options. "